Enoxaparin sodium
Enoxaparin, Inhixa, Lovenox (enoxaparin sodium) is an oligosaccharide pharmaceutical. Enoxaparin sodium was first approved as Lovenox (preservative free) on 1993-03-29. It is used to treat myocardial infarction, postoperative complications, pulmonary embolism, thromboembolism, and thrombophlebitis amongst others in the USA. It has been approved in Europe to treat venous thromboembolism. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Enoxaparin, Lovenox (discontinued: Lovenox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enoxaparin sodium | NDA authorized generic | 2025-06-25 |
| enoxiluv kit | unapproved drug other | 2024-10-05 |
| lovenox | New Drug Application | 2025-06-03 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1650 | Injection, enoxaparin sodium, 10 mg |
Clinical
Clinical Trials
462 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thromboembolism | D013923 | — | — | 5 | 41 | 50 | 28 | 28 | 143 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 5 | 35 | 45 | 21 | 21 | 118 |
| Thrombosis | D013927 | — | — | 8 | 25 | 30 | 25 | 28 | 109 |
| Venous thrombosis | D020246 | — | I82.40 | 7 | 22 | 22 | 21 | 18 | 84 |
| Covid-19 | D000086382 | — | U07.1 | 3 | 15 | 19 | 11 | 12 | 55 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 6 | 8 | 15 | 9 | 10 | 45 |
| Embolism | D004617 | — | — | 4 | 6 | 15 | 10 | 9 | 41 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 10 | 7 | 4 | 21 |
| Infarction | D007238 | EFO_0009463 | — | — | 1 | 10 | 7 | 4 | 21 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 1 | 1 | 5 | 9 | 17 |
Show 68 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | 5 | — | 6 | 12 |
| Replacement arthroplasty knee | D019645 | — | — | — | 5 | 2 | — | — | 7 |
| Thrombophilia | D019851 | — | D68.59 | — | — | 1 | — | 5 | 6 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | 1 | 4 | — | 1 | 5 |
| Infections | D007239 | EFO_0000544 | — | — | — | 3 | — | 1 | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 2 | — | 1 | 4 |
| Fibrosis | D005355 | — | — | — | 2 | 2 | — | 1 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | 3 | — | — | 4 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | 2 | — | 1 | 3 |
| Fetal growth retardation | D005317 | EFO_0000495 | — | — | — | 2 | — | 1 | 3 |
Show 42 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | 1 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 3 | — | — | — | 3 |
| Morbid obesity | D009767 | EFO_0001074 | — | 2 | 1 | — | — | 1 | 3 |
| Pregnancy rate | D018873 | — | — | 1 | 1 | — | — | 1 | 3 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | 1 | 2 |
| Plasma cell neoplasms | D054219 | — | — | — | 2 | — | — | — | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | — | — | — | 2 |
| Intracranial thrombosis | D020767 | — | — | 1 | 2 | — | — | — | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 2 | — | — | — | 2 |
Show 28 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fetal death | D005313 | — | — | 2 | — | — | — | 2 | 4 |
| Cesarean section | D002585 | — | — | 1 | — | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
| Disease progression | D018450 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | — | — | 2 | 2 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 2 | 2 |
| Traumatic intracranial hemorrhage | D020198 | — | — | — | — | — | — | 2 | 2 |
| Heart valve prosthesis | D006350 | EFO_0003906 | — | — | — | — | — | 2 | 2 |
| Burns | D002056 | — | T30.0 | — | — | — | — | 2 | 2 |
| Blood coagulation | D001777 | GO_0007596 | — | — | — | — | — | 2 | 2 |
| Fertilization in vitro | D005307 | — | — | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Ecchymosis | D004438 | — | — | — | — | — | — | 2 | 2 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | — | 1 | 1 |
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Enoxaparin sodium |
| INN | enoxaparin sodium |
| Description | Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 679809-58-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201476 |
| ChEBI ID | — |
| PubChem CID | 772 |
| DrugBank | DB01225 |
| UNII ID | 8NZ41MIK1O (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Lovenox – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Enoxaparin – Amphastar Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Enoxaparin sodium
+
Enoxaparin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
Black-box warning for: Enoxaparin sodium, Enoxiluv kit, Lovenox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
37,231 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use